Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including special fluorinated agents and various fluorination processes [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the Renminbi [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 10, the company's stock price decreased by 1.01%, with a trading volume of 33.1865 million yuan and a turnover rate of 1.75%, resulting in a total market capitalization of 4.019 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 2.4753 million yuan today, indicating a lack of clear control by major investors [5][6].
金凯生科跌1.01%，成交额3318.65万元，今日主力净流入-247.53万